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Abstract 
Background: Several studies have reported that oral immunotherapy (OIT) is effective for children with cow’s milk 
(CM) allergy. These studies reported the efficacy of OIT in terms of desensitization, but did not describe sustained 
unresponsiveness to CM. The aim of this study was to evaluate the efficacy of the OIT protocol using microwave 
heated cow’s milk (MH-CM) in terms of 2-weeks-sustained unresponsiveness (2-weeks-SU) and safety.
Methods: Forty-eight children were enrolled in this study. Thirty-one children agreed to receive rush OIT using 
MH-CM (the OIT group) and another 17 children who did not want to receive rush OIT formed the untreated group. 
Rates of desensitization and 2-weeks-sustained unresponsiveness were compared between the two groups at 1 year 
after the start of OIT. We followed up these rates and safety data for another year and for longer in the OIT group.
Results: No children in the untreated group did not pass an open food challenge to CM. Of the 31 children in the OIT 
group, 14 (P = 0.002) achieved desensitization, and 8 (P = 0.036) achieved 2-weeks-SU to CM at 1 year from the start 
of OIT. Two years after the start of OIT, both the rate of desensitization and the rate of 2-weeks-SU in the OIT group 
significantly increased compared with the rates at 1 year (P = 0.025 and P = 0.008 respectively).
Conclusions: The rush OIT protocol using MH-CM was effective at inducing 2-weeks-SU s to CM and had a good 
safety profile in children with CM allergy.
Trial registration Approval number: 324, Registered 3 February 2009
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Oral immunotherapy
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Cow’s milk (CM) is a common food ingested by children, 
and is the second most common immediate-type food 
allergy in Japanese children [1]. Allergen avoidance is the 
basic approach for the management of food allergy until 
clinical tolerance is confirmed. Although 50 % of children 
have tolerance to CM by 5  years of age and increasing 
to 75  % by their early teenage years [2], some children 
experience persistent allergic reactions [3, 4]. Oral immu-
notherapy (OIT) for food allergy has often been used for 
young children with CM allergy [6–15]. However, effi-
cacy of OIT was only previously described in terms of 
desensitization and also there are no reports of sustained 
unresponsiveness and efficacy of following cow’s milk 
oral immunotherapy (CM-OIT) using microwave heated 
cow’s milk (MH-CM). Therefore, the true efficacy of OIT 
for CM allergy is unclear.
Kim et  al. previously showed that the addition of 
baked milk to the diet of children tolerating such foods 
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appears to accelerate the development of unheated-milk 
tolerance compared to strict avoidance [16]. An explana-
tion of this observation might be that the high tempera-
ture reduces allergenicity by destroying conformational 
epitopes of milk proteins that subsequently it promotes 
unheated CM tolerance. Another recent study reported 
that MH-CM reduced allergic responses in a mouse aller-
gic model [17].
No study has been performed to investigate OIT for 
children with CM allergy using MH-CM. The aim of the 
present study was to evaluate the sustained unresponsive-
ness and safety of an OIT protocol using MH-CM in chil-
dren with CM allergy compared with an untreated group.
Patients and methods
Study design
A prospective, longitudinal, intervention study was per-
formed from June 2010 to March 2015 in the Depart-
ment of pediatrics of Kansai Medical University Hospital, 
Osaka, Japan. The study protocol was not registered in 
the official internet registration system in Japan, but was 
approved by the Institutional Ethics Committee of Kan-
sai Medical University, which included defining the out-
comes prospectively.
Patients
Inclusion criteria were as follows: aged 5–18  years and 
persistent CM allergy within the 2 weeks before the start 
of CM-OIT that was confirmed by (1) positive clini-
cal history, (2) positive food challenge test to CM and 
(3) level of CM specific immunoglobulin E (sIgE, CAP-
Phadia, Uppsala, Sweden) to CM above 0.35 kUA/L. We 
ensured that families had adequate information regard-
ing the study and understood the implications of par-
ticipation. Signatures designating informed consent 
were obtained. Exclusion criteria were as follows: severe 
atopic dermatitis and uncontrolled asthma (baseline 
FEV1  <  80  % of predictive value) according to Japanese 
pediatric guideline for the treatment and management of 
bronchial asthma [18].
We enrolled 48 children who met these criteria. Those 
who agreed to treatment were assigned to the treat-
ment group (OIT group), and those who did not want 
to receive treatment were assigned to the control group 
(the untreated group). This allocation was not done in 
a random manner and was based on the decision of the 
children and parents. The patients in the untreated group 
were followed up at 10–14  months, and oral food chal-
lenge (OFC) and blood examinations were repeated.
Oral food challenge
All CM challenges were open challenges, and were per-
formed at hospital settings and supervised by physicians. 
Clinical features of a reaction to CM were investigated 
for clinical purposes via an OFC as described previ-
ously [19]. A double-blind placebo-control food chal-
lenge is the gold standard for clinical studies, but is 
time-consuming in general practice. We could not assess 
subjective symptoms by OFC. Therefore, if patients had 
subjective allergic symptoms such as nausea, abdomi-
nal pain, sore throat, or itching, we increased the load-
ing dose until the objective symptoms appeared. During 
the challenge, full emergency equipment was at hand. 
Prior to enrollment in the study, the children’s parents 
provided informed consent. Patients were asked to avoid 
anti-histamine use for 72 h before the OFC, but topical 
steroids were allowed. Patients were admitted to our day 
clinic in the morning. The challenge material for the OFC 
was fresh CM. The procedure is described in detail in 
Table 1. The challenge was interrupted if children dem-
onstrated unambiguous clinical reactivity or after the 
administration of 40 mL of CM. Following the cessation 
of CM feeding, all children were observed for at least 
3 h. In cases of obvious allergic symptoms (such as rash, 
coughing, vomiting, or diarrhea) to loading doses of less 
than 40 mL CM positivity was indicated; otherwise, CM 
negativity was indicated. The threshold dose was defined 
as the last dose in OFC at which only objective symptoms 
occurred and the levels of severity of allergy to CM were 
assessed by Sampson’s grading score [20].
We also used MH-CM for OFC before OIT to define 
the initial dose of MH cow’s milk oral immunotherapy. 
Fresh CM was warmed in a microwave oven at 550 W for 
100  s and then cooled to room temperature before the 
OFC. The MH-CM food challenge was only performed 
with the OIT group immediately before the start of OIT.
Oral immunotherapy
OIT was performed within 2  weeks of the OFC using 
fresh CM. All the patients were admitted to our hospital. 
The OIT was performed following a previously described 
method [19]. The OIT protocol is described in detail 
in Table 1. The OIT consisted of two phases: (1) a rush 
phase, and (2) a maintenance phase.
After patients had undergone the maintenance phase 
followed by the rush phase, we evaluated whether patients 
in the OIT group were desensitized or had sustained 
unresponsiveness to CM at 1-, 2-, 3- and 4-year follow-
up. When patients ingested 200 mL of fresh CM daily for 
2  months without adverse events, they were considered 
desensitized to CM. If there were no adverse events for 
2  months with a daily intake of 200  mL of fresh CM, a 
CM-OFC was performed at 2 weeks after discontinuation 
of the daily administration of 200 mL of fresh CM. Dur-
ing the 2 weeks the patient continues strictly elimination 
of CM products. Briefly, the CM-OFC was undertaken 
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using the total 200 mL of fresh CM. The initial dose was 
set at 15 mL, and the increased at 30, 60 mL, and finally 
95  mL (total 200  mL) every 30  min. If the result of the 
CM-OFC was negative, the patient was defined as hav-
ing 2-weeks-sustained unresponsiveness (2-weeks -SU) 
for CM. Additionally, after the positivity of CM-OFC, the 
patient continued a daily intake of 200 mL of fresh-CM. 
After patients showed, 2-weeks-SU, the patients were free 
to ingest CM or CM-containing products.
Twenty of the OIT patients were followed for 4  years 
after the initiation of CM-OIT and 30 were followed for 
3  years. In comparison, in the untreated group, patients 
continued the elimination diet of CM and CM products 
after their OFCs. One year after the initial OFC, OFC with 
fresh CM was performed for the untreated group, and the 
results were compared with their previous OFC results.
Laboratory tests
Blood samples were collected before starting the rush 
OIT and at 1 and 2 years after the start of OIT.
Analyses
Two statistical analyses were performed: (1) comparison 
of the rates of desensitization and 2-weeks-SU at 1 year in 
the OIT and the untreated groups at 1 year, and (2) com-
parison of the rates of desensitization and 2-weeks-SU in 
the OIT group at 1- and 2-year follow-ups. Furthermore, 
we statistically analyzed the same factors indicated in 
Table 2 among children in the OIT group, to determine 
whether the baseline characteristics differed between the 
patients who achieved 2-weeks-SU to 200  mL of fresh 
CM at 2 years after the start of OIT and those who failed 
to achieve 2-weeks-SU.
Statistics
We statistically evaluated the clinical outcome of the OIT 
group (31 children) and the untreated group (17 children) 
at 1 year, using a 2-sided alpha level of 0.05, to detect a 
significant difference between the 2 groups. Using Fish-
er’s exact test and the Mann–Whitney U-test tested base-
line characteristics of the patients. Fisher’ exact test was 
used to evaluate between-group differences with regard 
to achieving desensitization and 2-weeks-SU to 200  mL 
of CM at 1-year follow-up. We also evaluated the differ-
ences in achieving a remission stage at the 1- and 2-year 
follow-ups within the OIT group using the Wilcoxon sign 




The baseline characteristics of these subjects are shown 
in Table 2; no significant differences were noted between 
the 2 groups.
Table 1 Oral food challenge and Rush OIT protocol
OIT oral immunotherapy, CM cow’s milk, OFC open food challenge, MH-CM microwave heated cow’s milk
a Grade of anaphylaxis according to Sampson’s score [20]
Oral food challenge
Procedure Open food challenge
Materials Fresh CM or MH-CM (heated for 100 s in 550 W microwave oven) or
Initial dose 0.1 mL
1 mL (if no anaphylaxis is suspected)
Subsequent dose 0.2, 0.5, 1,2, 5. 10, 20 and 40 mL
2, 5, 10, 20 and 40 mL (if no anaphylaxis is suspected)
Interval Every 30 min
Threshold dose Defined as the last dose in OFC at which only objective symptoms occurred and the levels of severity of allergy to CM [20]
Rush OIT
Initial dose Starting approximately at a tenth of the threshold dose determined at OFC using MH-CM 1.2-fold for each patient
Increase in dose Starting with MH-CM, the dose was increased approximately 1.2-fold every time
Ingest MH-CM 2–4 times a day at 2-h intervals
If gradea 2 or 3 develops, the same dose or the previous tolerated dose was repeated
If gradea 4 develops, OIT was stopped and the previous tolerated dose was repeated on the next day
When reaching 200 mL of MH-CH, the ingestion was once a day
No further increases in dosage because of repeated adverse events, after the highest tolerated dose was continued for 3 
consecutive days without any allergic reaction, the rush OIT was terminated
Maintenance Ingest the maintenance dose of 200 mL of MH-CM everyday for maintenance at home
If the subject did not reach the target dose of 200 mL of MH-CM, the loading dose was gradually increased by 1 mL per day 
until the target dose of 200 mL was reached and the dose was continued
MH-CM to fresh CM In cases where no adverse reactions were observed for 2 months during a daily intake of 200 mL of MH-CM, the time spent 
heating the CM in the microwave oven was gradually shortened by 10 s every week
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Clinical outcomes
Study enrollment and outcomes are shown in Fig. 1 and 
Table 3. Fourteen of 31 children (42 %) in the OIT group 
were categorized as desensitized to fresh CM at the 
1-year follow-up, whereas none in the untreated group 
passed an oral food challenge. In addition, there was a 
statistically significant difference between the 2 groups 
(P = 0.002). In the untreated group, the threshold doses 
(median 1 mL and range 0. 5–10 mL) and severity levels 
of allergy (median 2 and range 1–3) to CM in the initial 
OFC was not significantly different to the threshold doses 
(median 1.75 mL and range 0.1–40 mL) and severity lev-
els of allergy (median 2 and range 1–4) in the second OFC 
(P = 0.913, P = 0.688), respectively. The repeated OFC in 
the untreated group was performed at the 1-year interval 
(median: 12 months and range: 10–14 months). In addi-
tion, 7 of 31 children (21 %) in the OIT group showed a 
significant induced 2-weeks-SU to CM in contrast to 0 
of 17 children in the untreated group at 1-year follow-
up (P =  0.036) (Table  3). By the 2-year follow-up, both 
the rates of desensitization and 2-weeks-SU sustained 
in the OIT group were significantly increased compared 
with the rates at the 1-year follow-up (P  =  0.025 and 
P  =  0.008, respectively, by Wilcoxon rank test). Both 
the rates of desensitization and 2-weeks-SU gradually 
increased every year and reached 85 and 70  %, respec-
tively, by 4 years (Table  3). Two to 3 years after achiev-
ing, 2-weeks-SU, we followed the patients and confirmed 
that the patients did not experience any adverse events 
including oral itch after the ingestion of CM or CM prod-
ucts, including CM dependent exercise-induced anaphy-
laxis. Patients did not experience any adverse events in 
the follow-up period. 
The levels of CM-sIgE decreased significantly in the 
OIT group (median CM-sIgE level, 25.0–12.2 kUA/L) 
during 1-year follow-up. The levels of CM-sIgE also 
decreased in the untreated group (median CM-sIgE level, 
29.2–27 kUA/L) between the initial OFC and the OFC at 
1 year-interval.
Threshold dose and grade of anaphylaxis using MH‑CM 
in OFC
Before the rush OIT using MH-CM, OFC using MH-CM 
was performed. The threshold dose (median 10 mL and 
range 1–40  mL) was significantly higher for patients 
using MH-CM than for the patients using fresh CM 
(median 2 mL and range 0.1–40 mL) (P = 0.014) (Fig. 2). 
In addition, the severity of the grade of allergic reaction 
was milder for patients who received MH-CM compared 
with that for patients receiving fresh CM (P  =  0.036) 
(Fig. 2).
Skin prick test
Before the rush OIT, a skin prick test (SPT) was per-
formed in 10 of 21 patients in the OIT group using 
MH-CM and fresh CM. The median wheal size of SPT 
Table 2 Baseline characteristics of  patients in  the study 
group
CM cow’s milk, OIT oral immunotherapy, OFC open food challenge
a  Severity of asthma according to Japanese Pediatric Guideline for the 
treatment and management of bronchial asthma [21]
b  Grade of anaphylaxis according to Sampson’s score [20]
Characteristic Group P value
OIT (N = 31) Untreated  
(N = 17)
Gender (male) 23 14 0.396
Age at the challenge test
 Median 9 7 0.179
 Range (5–17) (5–16)
Initial total IgE level (IU/mL)
 Median 871 935 0.940
 Range (90–21966) (122.7–30725)
Initial CM-specific IgE level (kUA/L)
 Median 25 29 0.407
 Range (0.9–5730) (0.56–6290)
Initial casein-IgE level (kUA/L)
 Median 21.5 28.4 0.693
 Range (1.1–7210) (1.12–8350)
Initial β-lactoglobulin-IgE level (kUA/L)
 Median 2 1.05 0.425
 Range (0–61.8) (0.05–75.3)
Presence of other food allergiesa
 No 10 (32 %) 3 (18 %) 0.229
 Yes 21 (68 %) 14 (82 %)
Frequency of anaphylaxis at accidental ingestion
 Never 9 (29 %) 2 (12 %) 0.109
 Once 12 (39 %) 6 (35 %)
 2–10 times 10 (32 %) 9 (53 %)
 >10 times 0 0
Atopic dermatitis 13 18 0.48
Asthma
 Severity of asthmaa 14 (80 %) 10 (59 %) 0.376
 Intermittent 3 (45 %) 2 (12 %)
 Moderate 11 (35 %) 8 (47 %)
 Persistent 0 0
Threshold dose of CM at OFC (mL)
 Median 2 2 0.337
 Range (0.1–40) (0.5–10)
Grade of allergic reaction at OFCb
 1 8 (26 %) 2 (12 %) 0.823
 2 13 (42 %) 12 (71 %)
 3 6 (19 %) 3 (18 %)
 4 4 (13 %) 0 (0 %)
Page 5 of 10Takahashi et al. Allergy Asthma Clin Immunol  (2016) 12:44 
(median 10.5  mm and range 7–16  mm) using MH-CM 
was not statistically different compared with that of SPT 
using fresh CM (median 11.5 mm and range 7–16 mm) 
(P = 0.878 by Wilcoxon rank test).
Baseline characteristics in the OIT group according 
remission and continued intolerance
There were no significant differences of threshold dose 
and severity of the grade of allergic reaction to CM 
Table 3 The rate of desensitization and 2-weeks-sustained unresponsiveness for cow’s milk allergy in the oral immuno-
therapy group and the untreated group
OIT oral immunotherapy, OFC open food challenge
* P = 0.002 by Fisher’s exact test
** P = 0.036 by Fisher’s exact test
# P = 0.025 by Wilcoxon signed rank test
## P = 0.008 by Wilcoxon signed rank test
a Patients in untreated groups continued complete elimination of cow’s milk and a year later were performed open food challenge using fresh cow’s milk was 
performed
OIT (N = 31) Untreated group 
(N = 17)
Desensitization Two‑weeks‑sustained  
unresponsiveness
Pass OFC
At 1-year follow-up 14/31 (45%)*, # 7/31 (21%)**, ## 0/17 (0%)*, **,a
At 2-year follow-up 18/30 (60%)# 14/30 (47%)##
At 3-year follow-up 21/30 (70%) 16/30 (53%)
At 4-year follow-up 17/20 (85%) 14/20 (70%)
Study entry : 48
Untreated group : 17
1-year OFC
SU : 0 Not SU : 17
2-year
OIT group : 31
Desensitization
Yes : 14 No : 17
SU : 7 Not SU : 7
OFC
OIT : 23 1: no follow up 
Desensitization
Yes : 11 No : 12




Yes : 7 No :9
SU : 2 Not SU : 5
OFC
OIT : 7 7: no follow up 
Desensitization
Yes : 4 No : 3






Fig. 1 Study enrollment and outcomes of OIT oral immunotherapy with CM cow’s milk. (Hash) After the achievement of 2-weeks-sustained unre-
sponsiveness, the patients are followed for 2–3 year and they are able to ingest CM and CM products freely without any adverse events. OFC open 
food challenge
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at OFC between the patients who achieved 2-weeks-
SU and those who failed to achieve 2-weeks-SU by 
the 1-year follow up. However, the following factors 
were significantly different between the patients who 
achieve 2-weeks-SU and those who did not (Table  4): 
initial serum CM-sIgE level (P  =  0.0006), casein-
sIgE level (P  =  0.0005), β-lactoglobulin-sIgE level 
(P = 0.017), and severity of asthma (P = 0.03).
Safety data during the OIT period
Table 5 shows the average frequencies of adverse events 
that occurred per dose in each subject either at hospital 
or at home. In the rush phase of OIT (in hospital), the 
average of adverse events per subject per dose was 0.167. 
According to Sampson’s classification [20], 0.113 of sub-
jects had grade 1 adverse events, and 0.035 was grade 2, 
0.017 were grade 3 and 0.002 was 4. At home during the 
following year, the average of adverse events per subject 
per dose was 0.085 and 0.041 of subjects had grade 1 
adverse events, 0.035 were grade 2, 0.01 were grade 3 or 
0.0004 were 4. At home between years 1 and 2, the aver-
age of adverse events per subject per dose was 0.044 and 
0.024 of subjects had grade 1 adverse events, 0.013 were 
grade 2, 0.0005 were grade 3 or 0.0002 were 4.
For the treatment of these symptoms, 21 of 31 (64 %) 
children received medication at hospital. The aver-
ages of those receiving treatments per subject per dose 
are shown in Table 2. The number of patients receiving 
oral anti-histamines nebulized β-2 agonists, nebulized 
epinephrine agonists, oral dexamethasone, and intra-
venous steroids gradually decreased over the 2 study 
years. However, in the intolerant group, mild and mod-
erate adverse events occurred and were treated by anti-
histamines or nebulized β-2 agonists. Three patients 
each received a single epinephrine injection and one 
received three epinephrine injections at hospital. Four 
patients each received a single epinephrine injection, 
one received two epinephrine doses and one received 
three doses of epinephrine at the 1-year follow-up. In 
addition, these children did not achieve desensitization 
by 2 years after the start of OIT.
Discussion
The present study described the efficacy and safety of 
OIT using MH-CM for children with severe CM allergy 
compared with an untreated group. Three randomized 
control trials of CM-OIT previously reported significant 
differences of the threshold dosage and desensitization 
rates between patients who underwent OIT and those 
who maintained an elimination diet [5, 8, 9]. The suc-
cess rate for desensitization ranged from 36 to 67 %. In 
our study, the desensitization rates were 45, 60, 70 and 
85 % at 1, 2, 3 and 4 years after starting OIT, respectively. 
The three previous studies did not describe the results 
of CM sustained unresponsiveness [5, 8, 9], although 
one study described the rate of sustained unresponsive-
ness CM-OIT [21] in which 75  % of patients were suc-
cessfully desensitized; however, patients who passed the 
OFC 2  weeks after ceasing the OIT included 27.1  % of 
patients on CM and those patients might have achieved 
sustained unresponsiveness. The published rates for sus-
tained unresponsiveness are similar to those obtained 
in our study, but the rates of achieving desensitization 
were higher than in our study. This difference might be 
explained by the different protocols used or by the differ-
ent study populations.
The period following the discontinuation of OIT was 
relatively short (2  weeks) to assess sustained unrespon-
siveness. Although this approach was selected to be in 
line with NIAID–FDA recommendations food allergy 
clinical trial design at the time the study was designed 
and registered [22], it is acknowledged that a longer 
period of at least 4 weeks after discontinuation of treat-
ment would now be advised. We plan to perform a longer 
period follow-up study (5 or more years after OIT) in 
which subjects will undertake an OFC after 4–8 weeks of 
secondary CM elimination to assess prolonged sustained 
unresponsiveness.
MH-CM is prepared by heating in a microwave oven 
for 100  s. The temperature of MH-CM is almost 60  °C 
and is not aggregated. Before the intake of CM, MH-CM 














Threshold dose Grading score
Fig. 2 Changes of the threshold dose and the severity of the grade 
of anaphylaxis by Samson’s grading score [20] at OFC open food 
challenge using fresh CM cow’s milk and microwave heated cow’s 
milk (MH-CM). The MH-CM food challenge was only performed with 
the OIT group at the start of OIT. Fresh CM was heated in a microwave 
oven at 550 W for 100 s and the cooled to room temperture before 
the OFC
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Table 4 Baseline characteristics of patients in the intolerance group and the 2-weeks -sustained unresponsiveness group






Gender (male) 12 10 0.637
Age at the challenge test
 Median 7 10 0.469
 Range (5–17) (6–15)
Initial total IgE level (UA/mL)
 Median 1016 497 0.165
 Range (202–21,966) (90–6337)








Initial casein-IgE level (kUA/L)
 Median 83.9 7.445 <0.001
 Range (1.1–7210) (1.12–86.9)
Initial β-lactoglobulin-IgE level (kUA/L)
 Median 8.6 1.66 0.017
 Range (0.2–23.8) (0.0–17.4)
Presence of other food allergiesa
 No 5 (29 %) 5 (36 %) 0.503
 Yes 12 (71 %) 9 (64 %)
Frequency of adverse events/child/dose (%)
 Total events 17 7.3 0.503
 Grade 1 8 3.6
 Grade 2 3.6 0
 Grade 3 2.4 0
 Grade 4 0 0
Atopic dermatitis 3 (18 %) 1 (7 %) 0.378
Asthma
 Severity of asthmaa
 Intermittent 1 (6 %) 3 (21 %) 0.030
 Moderate 9 (53 %) 7 (7 %)
 Persistent 0 0
Threshold dose of fresh CM at OFC (mL)
 Median 1.5 5 0.790
 Range (0.1–40) (1–20)
Threshold dose of heated CM at OFC (mL)
 Median 10 15 0.091
 Range (1–40) (5–40)
Grade of allergic reaction at OFC (fresh CM)b
 1 3 (18 %) 5 (36 %) 0.415
 2 7 (41 %) 6 (43 %)
 3 3 (18 %) 3 (21 %)
 4 4 (23 %) 0 (0 %)
Grade of allergic reaction at OFC (heated CM)b 8 (41 %) 9 (64 %) 0.415
 1 6 (35 %) 3 (21 %)
 2 2 (12 %) 1 (7 %)
 3 1 (6 %) 1 (7 %)
CM cow’s milk, OFC open food challenge
a Severity of asthma according to Japanese Pediatric Guideline for the treatment and management of bronchial asthma [21]
b Grade of anaphylaxis according to Sampson’s score [20]
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MH-CM-OFC significantly increased compared with 
that of fresh CM-OFC. In addition, the severity of aller-
gic symptoms in the MH-CM-OFC was significantly less 
than that for the fresh CM-OFC. Three children had a 
decreased threshold to MH-CM, two of which showed 
decrease in their grading score (4-1 and 2-1). The third 
child showed no change in grading score. The grading 
score of the child receiving fresh CM and MH-CM had 
scores of 2 and 2, respectively, and showed sporadic 
cough. A reason why there was no difference in grading 
score and decreased threshold to MH-CM between the 
two OFCs might be unclear.
In a study by Mecherfli et  al. to examine whether the 
observed microwave effects were dependent upon tem-
perature, peptic hydrolysis was studied with conventional 
heating using the same temperatures as those attained 
with different microwave wattages: 43.2, 51.7 and 63.5 °C 
for 50 W (5 min), 100 W (3 min) and 200 W (3 min) irra-
diation, respectively [17]. They found a significant effect 
on peptic hydrolysis of purified β-lactoglobulin at 200 W 
(3  min) with 52  % protein degradation as estimated by 
electrophoretic densitometry relative to conventional 
heating at an identical temperature. Thus, microwave 
effects on peptic hydrolysis were significant compared 
with conventional heating to the same temperature. 
We measured the temperature of MH-CM at 550 W for 
100 s, and found the value to be 60 °C. The effect on our 
microwave-heated method at 550 w (100  s) was sup-
posed to be equal to that of the method at 200 w (3 min). 
Mecherfli et  al. also confirmed this hydrolysis effect by 
pepsin using the sera of young patients allergic to bovine 
whey proteins using an anti-IgE immunoblotting assay 
[23]. These results suggest that microwave-heated treat-
ment reduces the allergenicity of cow milk proteins con-
taining β-lactoglobulin by enzymatic digestion in the 
intestine. Therefore, in the MH-CM-OFC, patients had 
higher threshold doses and fewer allergic symptoms than 
those in the fresh CM-OFC, though there were no signifi-
cant differences in the wheal diameter by SPT between 
heated CM and fresh CM groups. A significant difference 
between the two OFCs was observed, but this was small. 
Therefore, future investigations should use a larger num-
ber of the two OFCs or double blind placebo control study 
of OIT using both MH-CM and fresh CM to elucidate 
whether MH-CM is a better intervention than fresh CM.
Adverse events in the MH-CM-OIT group were also 
mild. It is difficult to compare the frequencies of adverse 
events during OIT with other studies because the meth-
ods of calculating adverse reactions and the classifica-
tion of adverse reactions are different among studies. 
The only way to assess the adverse events is by using 
the percentage of patients requiring epinephrine. The 
percentage of patients requiring epinephrine in previ-
ous studies was 6.7 [6], 13.3 [8] 16.7 [5], and 30.8 % [9], 
whereas in our study it was 12.9 %. The two studies that 
had lower rates of epinephrine usage [6, 8] enrolled dif-
ferent age populations and use a different dosing method 
compared with our study. The study design and patient 
populations of the two studies with higher rates of epi-
nephrine usage [5, 9] were similar to those of our study. 
The percentages of epinephrine treatment in these two 
studies were higher than that in our study. Based on 
these findings, MH-CM-OIT may be relatively safe com-
pared with fresh CM-OIT.
Table 5 Averages of reactions and treatments per dose per child in the rush phase of oral immunotherapy (in hospital), 
at 1 year (at home) and at 1–2 years (at home)
Each data express averages of reactions and treatments per dose per child
a Grade of anaphylaxis according to Sampson’s score [20]
b Total numbers of injection
Reactions per dose per child
Total Grade 1a Grade 2a Grade 3a Grade 4a
Rush phase 0.167 0.113 0.035 0.017 0.002
1 year 0.085 0.041 0.035 0.01 0.0004
1–2 years 0.044 0.024 0.013 0.0005 0.0002
Treatments per dose per child










Rush phase 0.039 0.02 0.02 0.04 0.003 0.003(6)b
1 year 0.02 0 0.017 0.027 0.0009 0.0006(9)b
1–2 years 0.01 0 0.005 0.02 0 0.0001(1)b
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We statistically analyzed the factors in Table 4 for chil-
dren in the OIT group to determine whether there was a 
difference in baseline characteristics between the patients 
who achieved 2-weeks-SU to 200  mL of fresh CM and 
those who failed to do so. There were several significant 
differences between the patients who achieved 2-weeks-
SU and those who failed to achieve 2-weeks-SU includ-
ing initial serum CM-sIgE level (P = 0.0006), casein-sIgE 
level (P = 0.0005), β-lactoglobulin-sIgE level (P = 0.017), 
and severity of asthma (P  =  0.03) (Table  2). Similar 
results using fresh CM-OIT protocol were reported by 
Vázquez-Ortiz et  al. [24]. Although they analyzed the 
baseline characteristics of the two groups by safety data. 
Cox proportional hazard multivariate regression model 
identified three variables (CM-sIgE, CM-skin prick test 
and Sampson’s severity grades at baseline food challenge) 
as independent risk factors for the persistence of allergic 
reactions. It is very interesting to note that the factors 
predicting prognosis are serum CM-sIgE level than the 
threshold dose by OFC.
There were several limitations in our study. First, the 
study was not randomized. The observational period of 
the untreated group was limited to 1 year and we could 
not extend it because all the patients wanted to start 
either slow-type home-based OIT or rush type OIT 
after 1-year of observation. Therefore, we could not set 
a control group for the whole study period. Second, the 
immunological markers assayed were limited to IgE lev-
els, and we were not able to include serum IgG4 levels 
or the SPT. Third, multiple regression analysis was used 
to identify independent factors to predict tolerance and 
reactivity. However the sample size was too small to 
determine whether the factors were significant. Fourth, 
the OIT and untreated groups are not equivalent in terms 
of their demographics, because there was a trend in the 
control group toward increased atopy (slightly higher 
total and CM-sIgE levels, increased percentage with 
other food allergies, increased percentage with moderate 
asthma), an increased percentage who had multiple prior 
episodes of anaphylaxis after accidental ingestion, and an 
increased percentage with grade 2 or higher anaphylaxis 
during initial OFC. These factors may be considered to 
cause a self-selection bias in the untreated group. Finally, 
we already had performed fresh CM-OIT in ten children 
before the start of the present study. We could not com-
pare the study group using fresh CM-OIT, because the 
study was different from the present protocol. However, 
our study is the first study to assess 2-weeks-SU in CM-
OIT compared with a control group using a MH-CM 
material.
Conclusions
In this study, we found that a rush OIT protocol using 
MH-CM was effective in a significant percentage of chil-
dren with CM allergy and showed a good safety profile. 
Furthermore, serum CM-sIgE levels might be useful to 
predict 2-weeks-SU and safety of CM-OIT.
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